Stocks · News reference
Benitec Biopharma shares are trading higher after the company announced that BB-301 pivotal trial remains on track to begin in mid-2027 and the final pivotal study design is expected to be confirmed in Q1 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NVIDIA To $200? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for HAS, NCMI, BNTC, KR, COST, IBP and CRWD; cut targets for DVN, SPCE and NVDA. NCMI upgraded to Buy.
Wedbush Raises Price Target on Benitec Biopharma to $20 From $17
Wedbush Securities has increased its price target for Benitec Biopharma Inc. from $17 to $20 while maintaining an 'Outperform' rating.
Benitec Biopharma Reports First Quarter Fiscal 2027 Financial Results and Provides Operational Update
Benitec Biopharma announced its financial results for the fiscal quarter ended September 30, 2026, and reported positive interim clinical data for its BB-301 program.
8-K filing — Benitec Biopharma Inc. (BNTC)
Filed: 2026-11-13 AccNo: 0001193125-26-459339 Size: 378 KB Item 2.02: Results of Operations and Financial Condition Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Benitec Biopharma Announces Positive Interim Clinical Results for BB-301 in OPMD
Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301, showing robust and durable improvements in swallowing function for patients with Oculopharyngeal Muscular Dystrophy (OPMD).